
CLAIMS

1. A compound of Formula (I),



(I)

or a pharmaceutically acceptable salt thereof,

wherein:

R^1 is hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, 3 to 10 membered heterocyclyl having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, 6 to 10 membered aryl, or 5 to 10 membered heteroaryl having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with 1 to 4 R^{1A}, which can be the same or different, wherein each R^{1A} is independently selected from halogen, cyano, nitro, oxo, C_{1-4} alkyl, C_{3-10} cycloalkyl, 3 to 10 membered heterocyclyl having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, 6 to 10 membered aryl, 5 to 10 membered heteroaryl having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, $-N(R^{1B1})(R^{1B2})$, $-O-R^{1B1}$, $-S-R^{1B1}$, $-C(O)N(R^{1B1})(R^{1B2})$, $-NR^{1B1}C(O)R^{1B2}$, $-NR^{1B1}C(O)N(R^{1B2})(R^{1B3})$, $-S(O)_{0-2}R^{1B1}$, $-S(O)_2N(R^{1B1})(R^{1B2})$, and $-NR^{1B1}S(O)_2R^{1B2}$, wherein each R^{1B1}, R^{1B2}, and R^{1B3} is independently hydrogen, C_{1-6} alkyl, or C_{3-6} cycloalkyl,

wherein each R^{1A} alkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with 1 to 4 R^{1C}, which can be the same or different, and wherein each R^{1C} is independently C_{1-4} alkyl, halogen, cyano, $-O-R^{1D1}$, or

-N(R^{1D1})(R^{1D2}), wherein each R^{1D1} and R^{1D2} is independently hydrogen or C_{1-6} alkyl, and

wherein each R^{1B1}, R^{1B2}, and R^{1B3} alkyl and each R^{1B1}, R^{1B2}, and R^{1B3} cycloalkyl is optionally substituted with 1 to 3 halogens; or

R^1 is -O-R^{1D1} or -N(R^{1D1}) (R^{1D2}), wherein each R^{1D1} and R^{1D2} is independently hydrogen, C_{1-6} alkyl, or C_{3-6} cycloalkyl, wherein each C_{1-6} alkyl, or C_{3-6} cycloalkyl is optionally substituted with 1 to 4 R^{1E}, which can be the same or different, wherein each R^{1E} is independently selected from halogen, cyano, hydroxy, oxo, C_{1-4} alkyl, C_{3-10} cycloalkyl, 3 to 10 membered heterocyclyl having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, 6 to 10 membered aryl, 5 to 10 membered heteroaryl having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, -O-R^{1F1}, –N(R^{1F1})(R^{1F2}), –C(O)N(R^{1F1}) (R^{1F2}), –NR^{1F1}C(O)R^{1F2}, –S(O)$_{0-2}$$R^{1F1}$, –S(O)$_2$N($R^{1F1}$)($R^{1F2}$), and –N$R^{1F1}$S(O)$_2$$R^{1F2}$, wherein each R^{1F1} and R^{1F2} is independently hydrogen or C_{1-6} alkyl, wherein each R^{1E} alkyl, cycloalkyl, aryl, and heteroaryl is optionally substituted with 1 to 3 R^{1G}, which can be the same or different, and wherein each R^{1G} is independently C_{1-4} alkyl, C_{1-4} alkoxy, hydroxy, halogen, or cyano;

R^2 is hydrogen or C_{1-6} alkyl optionally substituted with 1 to 3 substituents, which can be the same or different, independently selected from halogen, cyano, C_{1-4} alkoxy, and C_{3-10} cycloalkyl; or

R^2 is C_{3-6} cycloalkyl optionally substituted with 1 to 3 substituents, which can be the same or different, independently selected from halogen, cyano, C_{1-4} alkoxy, and C_{1-6} alkyl;

each R^3 is independently selected from deuterium, halogen, C_{1-6} alkyl, C_{3-6} cycloalkyl, -O-R^{2A1}, and -N(R^{2A1})(R^{2A2}), wherein the C_{1-6} alkyl is optionally substituted with 1 to 3 substituents, which can be the same or different, independently selected from C_{1-4} alkoxy and halogen, and wherein each R^{2A1} and R^{2A2} is independently hydrogen or C_{1-3} alkyl optionally substituted with 1 to 3 halogens, which can be the same or different;

n is 0, 1, 2, 3, or 4;

R^4 is C_{1-6} alkyl optionally substituted with 1 to 3 substituents, which can be the same or different, independently selected from halogen, cyano, C_{1-4} alkoxy, -C(O)N(R^{4A1}), and

-N(R^{4A1})(R^{4A2}), wherein each R^{4A1} and R^{4A2} is independently hydrogen, C_{1-6} alkyl, or C_{3-10} cycloalkyl; or

R^4 is C_{3-6} cycloalkyl or 3 to 6 membered heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein the cycloalkyl or heterocyclyl are optionally substituted with 1 to 3 substituents, which can be the same or different, independently selected from halogen, cyano, C_{1-4} alkyl, and C_{1-4} alkoxy;


each of X^1, X^2, X^3, and X^4 is independently selected from CH and N;

each Y^1 and Y^2 is independently hydrogen, deuterium, or C_{1-6} alkyl optionally substituted with 1 to 3 substituents, which can be the same or different, independently selected from deuterium, halogen, cyano, C_{2-3} alkynyl, C_{1-4} alkoxy, and -C(O)NH-($C_{1-4}H_{3-9}$); and

Z is C_{1-8} alkyl, C_{1-6} alkoxy, C_{3-6} cycloalkyl, C_{6-12} aryl, 3 to 12 membered heterocyclyl having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or 5 to 12 membered heteroaryl having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein the alkyl, alkoxy, cycloalkyl, aryl, heterocyclyl, or heteroaryl are each optionally substituted with 1 to 3 substituents, which can be the same or different, independently selected from halogen, cyano, C_{1-4} alkyl, C_{1-4} alkoxy, and C_{3-6} cycloalkyl, wherein the C_{1-4} alkyl is optionally substituted with 1 to 3 substituents, which can be the same or different, selected from C_{1-4} alkoxy and halogen; or


Y^1 and Z together with the carbon to which they are attached form C_{3-6} cycloalkyl, C_{6-12} aryl, 3 to 12 membered heterocyclyl having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or 5 to 12 membered heteroaryl having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein the cycloalkyl, aryl, heterocyclyl, or heteroaryl are each optionally substituted with 1 to 3 substituents, which can be the same or different, independently selected from cyano, C_{1-4} alkyl, C_{1-4} alkoxy, C_{6-10} aryl, and halogen, wherein the C_{1-4} alkyl is optionally substituted with 1 to 3 substituents, which can be the same or different, independently selected from C_{1-4} alkoxy and halogen, and wherein the C_{6-10} aryl is optionally substituted with 1 to 3 substituents, which can be the same or different, independently selected from C_{1-4} alkyl, C_{1-4} alkoxy, and halogen, and Y^2 is hydrogen or deuterium.

2. The compound or pharmaceutically acceptable salt thereof of claim 1, wherein the compound of Formula (I) or Formula (Ia) is of Formula (IIa):



(IIa)


3. The compound or pharmaceutically acceptable salt thereof of claim 1, wherein the compound of Formula (I) or Formula (Ia) is of Formula (IIb):



(IIb)


wherein each R^3 can be the same or different.

4. The compound or pharmaceutically acceptable salt thereof of claim 1, wherein the compound of Formula (I) or Formula (Ia) is of Formula (IIc):




(IIc)

5. The compound or pharmaceutically acceptable salt thereof of claims 1, wherein the compound of Formula (I) or Formula (Ia) is of Formula (IId):




(IId)

6. The compound or pharmaceutically acceptable salt thereof of claim 1, wherein the compound of Formula (I) or Formula (Ia) is of Formula (IIe):



(IIe)


7. The compound or pharmaceutically acceptable salt thereof of claim 1, wherein the compound of Formula (I) or Formula (Ia) is of Formula (IIf):



(IIf)

wherein each R^3 can be the same or different.


8. The compound or pharmaceutically acceptable salt thereof of claim 1, wherein the compound of Formula (I) or Formula (Ia) is of Formula (IIg):



(IIg)


wherein each R^3 can be the same or different.

9. The compound or pharmaceutically acceptable salt thereof of claim 1, wherein the compound of Formula (I) or Formula (Ia) is of Formula (IIh):




(IIh)

10. The compound or pharmaceutically acceptable salt thereof of claim 1, wherein the compound of Formula (I) or Formula (Ia) is of Formula (IIi):




(IIi)

11. The compound or pharmaceutically acceptable salt thereof of claim 1, wherein the compound of Formula (I) or Formula (Ia) is of Formula (IIj):




(IIj)

12. The compound or pharmaceutically acceptable salt thereof of claim 1, wherein the compound of Formula (I) or Formula (Ia) is of Formula (IIk):




(IIk)

13. The compound or pharmaceutically acceptable salt thereof of claim 1, wherein the compound of Formula (I) or Formula (Ia) is of Formula (III):




(III)

14. The compound or pharmaceutically acceptable salt thereof of claim 1, wherein the compound of Formula (I) or Formula (Ia) is of Formula (IIm):




(IIm)

15. The compound or pharmaceutically acceptable salt thereof of claim 1, wherein the compound of Formula (I) or Formula (Ia) is of Formula (IIn):



(IIn)


16. The compound or pharmaceutically acceptable salt thereof of claim 1, wherein the compound of Formula (I) or Formula (Ia) is of Formula (IIo):




(IIo)


17. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-17, wherein R^1 is hydrogen.


18. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-17, wherein R^1 is C_{1-6} alkyl or C_{2-6} alkynyl, each optionally substituted with 1 to 4 R^{1A}, which can be the same or different, wherein each R^{1A} is independently selected from halogen, cyano, hydroxy, C_{1-4} alkoxy, and C_{3-6} cycloalkyl.


19. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-17 and 18, wherein R^1 is $-CH_3$, $-CHF_2$, $-CF_3$, 

20. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-17, wherein R^1 is $-O-R^{1D1}$ or $-N(R^{1D1})(R^{1D2})$, wherein each R^{1D} and R^{1D2} is independently -H, $-CH_3$, $-C_2H_5$, or $-C(CH_3)_3$.

21. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-17 and 20, wherein R^1 is .


22. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-17, wherein R^1 is cyclopropyl or cyclobutyl, each optionally substituted with 1 to 4 R^{1A}, which can be the same or different, each independently selected from -F, -Cl, -CN, =O, -OH, -CH_3, -CH_2F, -CHF_2, -CF_3, -CH_2-OH, -CH_2-NH_2, -OCH_3, -NH_2, -NH-CH_2-CF_3, , -NO_2, cyclopropyl, isoxazyl, phenyl, pyridyl, and –C(O)NH_2, wherein each isoxazyl or pyridyl is optionally substituted with 1 to 2 -F or -CH_3.

23. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-17 and 22, wherein R^1 is .



24. The compound or pharmaceutically acceptable salt thereof of any one of claims 1 to 17, wherein the C_{5-8} bridged bicyclic cycloalkyl is bicyclopentanyl or bicyclooctanyl, each optionally substituted with 1 to 3 substituents, which can be the same or different, each independently selected from -F, -Cl, -OH, -CN, $-CH_3$, $-CH_2F$, $-CHF_2$, $-CF_3$, $-O-CH_3$, and oxetanyl.


25. The compound or pharmaceutically acceptable salt thereof of claim 24, wherein R^1 is



or .


26. The compound or pharmaceutically acceptable salt thereof of any one of claims 1 to 17, wherein the C_{5-10} spiro bicyclic cycloalkyl is spiropentanyl, spirohexanyl, spiroheptanyl, or spirodecanyl, each optionally substituted with 1 to 4 R^{1A}, which can be the same or different, wherein each R^{1A} is each independently selected from -F, -Cl, -OH, $-CH_3$, $-CH_2F$, $-CHF_2$, $-CF_3$, -CN, and $-O-CH_3$.

27. The compound or pharmaceutically acceptable salt thereof of claim 26, wherein R^1 is




, or .

28. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-17, wherein R^1 is azetidinyl, oxetyl, thietanyl, pyrrolidinyl, dioxolanyl, tetrahydropyranyl, piperidinyl, or morpholinyl, each optionally substituted with 1 to 4 R^{1A}, which can be the same or different, each independently selected from -F, -Cl, -OH, -CN, $-CH_3$, $-CH_2F$, $-CHF_2$, $-CF_3$, $-C_2H_5$, $-CH_2-CF_3$, and $-O-CH_3$.


29. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-17 and 28, wherein R^1 is .

30. The compound or pharmaceutically acceptable salt thereof of any one of claims 1 to 17, wherein the bridged bicyclic heterocyclyl is an oxabicyclohexanyl optionally substituted with 1 to 4 R^{1A}, which can be the same or different, wherein each R^{1A} is independently selected from -F, -Cl, -OH, -CN, $-CH_3$, $-CH_2F$, $-CHF_2$, $-CF_3$, and $-O-CH_3$.


31. The compound or pharmaceutically acceptable salt thereof of claim 30, wherein R^1 is .

32. The compound or pharmaceutically acceptable salt thereof of any one of claims 1 to 17, wherein the fused bicyclic heterocyclyl is an oxabicyclohexanyl optionally substituted with 1 to 4 R^{1A}, which can be the same or different, wherein each R^{1A} is independently



selected from -F, -Cl, -OH, -CN, $-CH_3$, $-CH_2F$, $-CHF_2$, $-CF_3$, and $-O-CH_3$.


33. The compound or pharmaceutically acceptable salt thereof of claim 32, wherein R^1 is .


34. The compound or pharmaceutically acceptable salt thereof of any one of claims 1 to 17, wherein the spiro bicyclic heterocyclyl is an oxaspiroheptane optionally substituted with 1 to 4 substituents, which can be the same or different, each independently selected from -F, -Cl, -OH, -CN, $-CH_3$, $-CH_2F$, $-CHF_2$, $-CF_3$, and $-O-CH_3$.

35. The compound or pharmaceutically acceptable salt thereof of claim 34, wherein R^1 is .

36. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-17, wherein R^1 is phenyl optionally substituted with 1 to 3 R^{1A}, which can be the same or different, wherein each R^{1A} is independently selected from -F, -Cl, -CN, or $-CH_3$.

37. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-17, wherein R^1 is imidazolyl, pyrazolyl, pyridinyl, oxazolyl, isoxazolyl, oxadiazolyl, pyridinonyl, pyrimidinyl, pyridazinyl, benzoisoxazolyl, pyrazolopyridinyl, imidazopyridinyl, or benzoimidazolyl, each optionally substituted with 1 to 3 substituents, which can be the same or different, each independently selected from -F, -Cl, -CN, $-CH_3$, $-CHF_2$, $-CF_3$, $-OCH_3$, $-NH_2$, $-N(CH_3)_2$, $-SO_2-CH_3$, , or .

38. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-17 and 37, wherein R^1 is 




39. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-38, wherein R^3 is $–CH_3$.

40. The compound or pharmaceutically acceptable salt thereof of claim 1 and 17-39, wherein Y_1 is C_{1-4} alkyl optionally substituted with 1 to 3 substituents, which can be the same or different, each independently selected from halogen, cyano, and C_{1-4} alkoxy, and Y_2 is hydrogen.

41. The compound or pharmaceutically acceptable salt thereof of claim 40, wherein Y_1 is $-CH_3$ or $-CH_2F$.











42. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-41, wherein Z is phenyl, optionally substituted with 1 to 3 sustituents, which can be the same or different, each independently selected from halogen and C_{1-4} alkyl.






43. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-42, wherein Z is






44. The compound or pharmaceutically acceptable salt thereof of any one of claims 1 to 43, wherein Z is pyridyl, optionally substituted with 1 to 3 substituents, which can be the same or different, each independently selected from -F, -Cl, -Br, and -CH_3.







45. The compound or pharmaceutically acceptable salt thereof of claim 43, wherein Z is














, 
, 
, 
, 
,

, 
, 
, 
, or 
.













46. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-45, wherein Y_1 is -CH_3 and Z is 
, 
, 
, 
,

or .













47. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-46, wherein Y_1 is -CH_3 and Z is 
, 
, or 
.













48. A compound selected from the group consisting of:














,

,

,

,

,

,








,

,

,

,

,

,

,

,

,

,

,

,








,

,

,

,

,

,

,

,

,

,

,

,



,

,

,

,

,

,

,

,

,

,

,

,














,

,

,

,

,

,

,

,

,

,

,

,














,

,

,

,

,

,

,

,

,

,

,

,



,

,

,

,

,

,








,

,

,

,

,

,






















,

,

,

,

,

,

,

,

,

,

,

,














,

,

,

,

,

,

,

,

,

,

,

,




























,

,

,

,

,

,










,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,
,
,
,
,
,
,
,
,
,
,
,











,

,

,

,

,

,

,

,

,

,

,

,














,

,

,

,

,

,

,

,

,

,

,

,














,

,

,

,

,

,

, and

,













or a pharmaceutically acceptable salt thereof.













49. A compound selected from the group consisting of:














,

,

,

,

,

,

,

,

,














,

,

,

,

,

,

,

,

,

,

,

,














,

,

,

,

,

,

,

,

,

,

,

,











,

,

,

,

,

,

,

,

,

,

,

,














,

,

,

,

,

,

,

,

,

,

,

,













,
,
,
,
,
,
,
,
,
,
,
,














,

,

,

,

,

,

,

,

,

,

,

,







,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,



,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,



,

,

,

, and

,

or a pharmaceutically acceptable salt thereof.

50. A compound or pharmaceutically acceptable salt thereof of claim 1, wherein the compound is



.

51. A compound or pharmaceutically acceptable salt thereof of claim 1, wherein the compound is




.

52. A compound or pharmaceutically acceptable salt thereof of claim 1, wherein the compound is




.

53. A compound or pharmaceutically acceptable salt thereof of claim 1, wherein the compound is




.

54. A compound or pharmaceutically acceptable salt thereof of claim 1, wherein the compound is




.

55. A compound or pharmaceutically acceptable salt thereof of claim 1, wherein the compound is




.

56. A compound or pharmaceutically acceptable salt thereof of claim 1, wherein the compound is




.


57. A compound or pharmaceutically acceptable salt thereof of claim 1, wherein the compound is




58. A compound or pharmaceutically acceptable salt thereof of claim 1, wherein the compound is



59. A compound or pharmaceutically acceptable salt thereof of claim 1, wherein the compound is




60. A compound or pharmaceutically acceptable salt thereof of claim 1, wherein the compound is




.

61. A compound or pharmaceutically acceptable salt thereof of claim 1, wherein the compound is



.

62. A compound or pharmaceutically acceptable salt thereof of claim 1, wherein the compound is



.

63. A pharmaceutical composition comprising a therapeutically effective amount of a compound, or pharmaceutically acceptable salt thereof, of any one of claims 1 to 62, and a pharmaceutically acceptable excipient.

64. The pharmaceutical composition of claim 63, further comprising an additional therapeutic agent.

65. Use of a therapeutically effective amount of a compound of any one of claims 1 to 62, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for of treating, stabilizing, or lessening the severity or progression of an LPAR1 mediated disease or condition.

66. The use of claim 65, wherein the LPAR1 mediated disease or condition is an interstitial lung disease (ILD).

67. The use of claim 65, wherein the LPAR1 mediated disease or condition is a chronic kidney disease (CKD).

68. The use of claim 65, wherein the LPAR1 mediated disease or condition comprises fibrosis.

69. The use of claim 68, wherein fibrosis is pulmonary fibrosis, renal fibrosis, hepatic fibrosis, ocular fibrosis, cardiac fibrosis, or systemic sclerosis.

70. The use of claim 69, wherein pulmonary fibrosis is idiopathic pulmonary fibrosis (IPF) or Progressive Fibrotic interstitial lung disease (PF-ILD).

71. The use of claim 65, wherein the LPAR1 mediated disease or condition is a liver disease.

72. The use of claim 71, wherein the liver disease comprises non-alcoholic steatoheptitis (NASH).

73. The use of claim 71 or 72, wherein the liver disease comprises Primary Biliary Cirrhosis (PBC) or Primary Sclerosing Choleangitis (PSC).

74. The use of claim 71 or 72, wherein the liver disease comprises portal hypertension.

75. The use of any one of claims 65-74, wherein the compound or pharmaceutically acceptable salt thereof is to be administered in combination with an additional therapeutic agent.

76. The pharmaceutical composition of claim 63 or the use of claim 75, wherein the additional therapeutic agent is one, two, three, or four additional therapeutic agents.

77. The pharmaceutical composition of claim 63, or the use of claim 75 or 76, wherein the additional therapeutic agent comprises an acetyl-CoA carboxylase (ACC) inhibitor, an apoptotic signal-regulating kinase (ASK-1) inhibitor, a farnesoid X receptor (FXR) agonist, fish oil, a glucagon-like peptide-1 receptor agonist, a peroxisome proliferator-activated receptor alpha (PPARα) agonist, or a TGFβ antagonist.